Vascular Anomalies in Pediatrics

Foley, Lisa S.; Kulungowski, Ann M.

doi:10.1016/j.yapd.2015.04.009

Cited by 28 publications

(43 citation statements)

References 118 publications

(140 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA), which are considered to be part of a histopathologic spectrum, are uncommon vascular tumors that can be challenging to treat . A potentially life‐threatening complication, Kasabach‐Merritt phenomenon (KMP), often occurs in patients with these tumors .…”

Section: Introductionmentioning

confidence: 99%

Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angioma

Wang

Guo

Duan

et al. 2018

Pediatric Dermatology

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angioma

Wang

Guo

Duan

et al. 2018

Pediatric Dermatology

View full text Add to dashboard Cite

show abstract

“…The lesions could be seen in any lymphatic-rich area, such as neck, axilla, groin, mediastinum, and retroperitoneum, but most commonly found in head and neck. [22] These lesions could involve different tissue planes, including mucosa, skin, subcutaneous tissue, and muscle. Although the molecular mechanism of LM is unknown, the emerging of more ideal laboratory models of LM and substantial studies on the genetics of lymphatic anomalies gradually unveils the secrets of LM.…”

Section: Discussionmentioning

confidence: 99%

Treatment of deep-seated facial microcystic lymphatic malformations with intralesional injection of pingyangmycin

Wang²,

Zheng

et al. 2016

Medicine

View full text Add to dashboard Cite

Treatment of microcystic lymphatic malformations (LMs) is still a great challenge to physicians in the field of managing vascular anomalies. Several kinds of treatment have been proposed for microcystic LMs, but the responses to these treatment modalities vary considerably among individuals. The aim of the study was to investigate the safety and efficacy of intralesional injection of pingyangmycin for microcystic LMs located in the deep facial region.Twenty-one consecutive patients with deep-seated facial microcystic LMs were treated with intralesional injection of pingyangmycin between March 2010 and April 2015. The patients received 2 to 8 injections, and the average session was 3.7. The therapeutic efficacy was accessed on the basis of the imaging findings and clinical measurements.Among the 21 patients, the clinical responses were excellent in 7 patients (33.33%), good in 9 patients (42.86%), fair in 3 patients (14.29%), and poor in 2 patients (9.52%). No severe side effects were encountered. Furthermore, therapeutic outcomes were significantly associated with lesion location (P = 0.006) and number of injections (P = 0.003).Our study supports that sclerotherapy with pingyangmycin is safe and effective for the treatment of deep-seated facial microcystic LMs.

show abstract

“…El comportamiento y la presentación de estas lesiones son heterogéneos porque pueden aparecer en cualquier parte del cuerpo, ser congénitas o manifestarse durante los primeros años de vida. 1,2 En 1982, Mulliken y Glowacki dividieron, por primera vez, las anomalías vasculares en: hemangiomas y malformaciones. 3 Posteriormente, en 1996, se formó la International Society for the Study of Vascular Anomalies (ISSVA).…”

Section: Introductionunclassified

Anomalías vasculares más frecuentes en pacientes pediátricos. Parte 1: Tumores vasculares

et al. 2020

View full text Add to dashboard Cite

Las anomalías vasculares son un grupo heterogéneo de alteraciones en los vasos sanguíneos y linfáticos. La International Society for the Study of Vascular Anomalies (ISSVA) las clasifica en: tumores y malformaciones vasculares. En este artículo (primera parte de dos) se revisan los principales tumores vasculares en pacientes pediátricos, su fisiopatogenia, manifestaciones clínicas, diagnóstico y tratamiento. Nos enfocaremos en el hemangioma infantil, hemangiomas congénitos, granuloma piógeno, angioma en penacho y hemangioendotelioma kaposiforme.El hemangioma infantil es el tumor vascular más frecuente, aparece en las primeras 4 semanas de vida y crece con rapidez, para posteriormente involucionar en la etapa preescolar. Se manifiesta como una neoformación vascular, de coloración eritematoviolácea, de tamaño variable. Los hemangiomas congénitos son más raros, están completamente desarrollados al nacimiento porque su crecimiento es intrauterino. El granuloma piógeno es el tumor vascular más frecuente, después del hemangioma infantil, y se manifiesta como una neoformación de color rojo-violáceo, exofítica; es de crecimiento rápido y sangra fácilmente. El angioma en penacho y el hemangioendotelioma kaposiforme, que algunos autores consideran espectros de una misma enfermedad, son tumores vasculares poco frecuentes que suelen aparecer en los primeros meses de vida y que se asocian con complicaciones hematológicas: fenómeno de Kasabach-Merritt, que puede poner en riesgo la vida del paciente.La clasificación adecuada de los tumores vasculares es indispensable para la correcta comunicación entre las especialidades implicadas, con el fin de establecer el diagnóstico correcto y planificar el tratamiento.

show abstract

Vascular Anomalies in Pediatrics

Cited by 28 publications

References 118 publications

Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angioma

Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angioma

Treatment of deep-seated facial microcystic lymphatic malformations with intralesional injection of pingyangmycin

Anomalías vasculares más frecuentes en pacientes pediátricos. Parte 1: Tumores vasculares

Contact Info

Product

Resources

About